



Caribou Biosciences to Participate in Upcoming Investor Conferences

February 12, 2026

BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

- **Citi 2026 Virtual Oncology Leadership Summit**, Virtual
February 19, 2026, with a fireside chat at 10:45 AM ET
- **Leerink Global Healthcare Conference**, Miami, FL
March 10, 2026, with a fireside chat at 8:00 AM ET
[Webcast](#)

For more information and link to the Leerink webcast, please visit the [Events](#) page on Caribou's website. The webcast will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the Company @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:

Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com